Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program. KT-621 parallel Phase 2b trials advancing in AD and asthma, with data e ...
Lansing State Journal on MSNOpinion
Viewpoint: It’s time to stop promoting people without preparing them
The skills that make someone a great individual contributor are simply not the same skills that make someone a great leader, ...
Company completes approximately 3,500 meters of drilling, begins receiving assay results from its infill-focused program, continues advancing the PEA and strengthens development capabilities with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results